Clinical Trial Update: Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a triple combination of belantamab mafodotin, lenalidomide, and daratumumab for relapsed/refractory or previously untreated multiple my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• DARZALEX (daratumumab)
• Revlimid (lenalidomide)

Snippet

Sponsor: Mayo Clinic | Conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma | Phase 1 | Status: TERMINATED